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Possession of the fast metabolizing alleles for alcohol dehydrogenase (ADH), ADH1B*2 and ADH1C*1, and the
null allele for aldehyde dehydrogenase (ALDH), ALDH2*2, results in increased acetylaldehyde levels and is
hypothesized to increase the risk of head and neck cancer. To examine this association, the authors undertook a
Human Genome Epidemiology review on these three genes and a pooled analysis of published studies on ADH1C.
The majority of Asians had the fast ADH1B*2 and ADH1C*1 alleles, while the majority of Caucasians had the slow
ADH1B*1/1 and ADH1C*1/2 genotypes. The ALDH2*2 null allele was frequently observed among Asians, though it
was rarely observed in other populations. In a pooled analysis of data from seven case-control studies with a total of
1,325 cases and 1,760 controls, an increased risk of head and neck cancer was not observed for the ADH1C*1/2
genotype (odds ratio = 1.00, 95% confidence interval: 0.81, 1.23) or the ADH1C*1/1 genotype (odds ratio = 1.14,
95% confidence interval: 0.92, 1.41). Increased relative risks of head and neck cancer were reported for the
ADH1B*1/1 and ALDH2*1/2 genotypes in several studies. Recommendations for future studies include larger
sample sizes and incorporation of relevant ADH and ALDH genes simultaneously, as well as other genes. These
considerations suggest the potential for the organization of a consortium of investigators conducting studies in this
field.
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ratio.
Editor’s note: This article is also available on the website
of the Human Genome Epidemiology Network (http://
www.cdc.gov/genomics/hugenet/default.htm).
Alcohol dehydrogenases (ADHs) are enzymes involved in
the metabolism of ethanol to acetaldehyde (1). Subsequent
conversion of acetaldehyde to acetate is catalyzed by the
mitochondrial enzyme aldehyde dehydrogenase (ALDH)
(figure 1). Most of the metabolism of alcohol and aldehyde
is carried out in the liver, although extrahepatic metabolism
has also been demonstrated in the stomach, gut, and upper
aerodigestive tract (2), including some potential metabolism
due to oral microflora in the oral cavity (3–5).
GENES
ADH1B and ADH1C
Human ADH exhibits different molecular forms resulting
in amino acid sequence differences of more than 30 percent
and specific tissue distributions. There are five different
classes of ADHs and seven different isoenzymes: alpha,
beta, and gamma in class I, pi in class II, chi in class III,
ADH7 in class IV, and ADH6 in class V. The class I ADH
subunits form homo- or heterodimers (αα, ββ, γγ, αβ, αγ,
βγ) (6). The three different class I gene loci, ADH1A (alpha),
ADH1B (beta), and ADH1C (gamma), are situated close to
each other in the region 4q21–23 (an older nomenclature is
ADH1, ADH2, and ADH3 (7)); only ADH1B and ADH1C are
polymorphic (8–11).
The polymorphic sites for ADH1B are Arg47His in exon 3
and Arg369Cys in exon 9 (12). The presence of a histidine
molecule at amino acid position 47 constitutes the *2 allele,
and the presence of a cysteine molecule at amino acid posi-
tion 369 constitutes the *3 allele. The polymorphic site for
ADH1C is Ile349Val in exon 8, and the presence of a valine
molecule at this amino acid position constitutes the
ADH1C*1 allele (13, 14). The alleles ADH1C*1 and
ADH1B*2 code for “fast” metabolism of ethanol; in vitro,
the ADH1C*1 allele increases oxidation by approximately
2.5-fold in comparison with ADH1C*2, whereas the
ADH1B*1/1 genotype has only 1 percent and 0.5 percent of
the oxidation capability of the ADH1B*1/2 and ADH1B*2/2
genotypes, respectively (15). Linkage disequilibrium
between ADH1C*1 and ADH1B*2 has been demonstrated in
several Caucasian populations (16).
ALDH2
Thus far, 17 ALDH genes have been identified in nine
ALDH genotype groups. A major human liver ALDH gene
is the mitochondrial ALDH2 in class II, located on chromo-
some 12q24.2. The ALDH2 gene contains an inactive
ALDH2*2 allele (substitution of lysine for glutamine at
amino acid position 487), which means that persons who are
homozygous are unable to oxidize acetaldehyde and those
who are heterozygous do so inefficiently (17, 18). For
heterozygous persons, given that the ALDH2 isoenzyme is a
tetramer and each subunit has a 50 percent chance of being
functional, only 1/16th of ALDH2 enzymes will be func-
tional (19). This leads homozygous and heterozygous
possessors of the ALDH2*2 allele to experience a build-up
of acetaldehyde that creates a toxic reaction, including
flushing, increased heart rate, and nausea.
Prevalence of gene variants
To estimate the prevalence of the ADH1B, ADH1C, and
ALDH2 polymorphisms in different populations, we
conducted a MEDLINE search (US National Library of
Medicine) using the terms “ADH2,” “ADH3,” “ADH1B,”
“ADH1C,” and “ALDH2,” each in combination with “preva-
lence” and “case-control.” The currently accepted nomencla-
ture for ADH1B and ADH1C is relatively new, and thus the
majority of studies we identified used the older nomencla-
ture. We attempted to identify genotype frequencies among
control populations from case-control studies, which usually
focused on alcoholism, or studies that focused on reporting
genotype frequencies. Studies that reported only allele
frequencies and not genotype frequencies were not included.
For the sake of brevity, we have not included genotype
frequencies from all studies in this report, and we excluded
studies based on small sample sizes (<100 subjects) when
several other reports on that particular ethnic group were
available.
The genotype frequencies of the ADH1B polymorphism in
different populations are shown in table 1 (20–41). The
ADH1B*1 “slow” allele was very common among Cauca-
sians, with approximately 95 percent having the homozy-
gous ADH1B*1/1 genotype and 5 percent having the
heterozygous ADH1B*1/2 genotype (38). The ADH1B*2/2
genotype was rarely observed in Caucasians. Conversely,
the ADH1B*2 allele was the most common allele in Asian
populations. In African populations, the ADH1B*1 allele
was the most common, although a third allele, ADH1B*3,
has also been reported (20, 21).
FIGURE 1. The metabolic pathway for alcohol. ADH, alcohol dehy-
drogenase; ALDH, aldehyde dehydrogenase. (Hypothesis: Fast ADH
metabolizing genes and slow ALDH metabolizing genes will lead to a
peak in acetaldehyde exposure and increased risk of alcohol-related
cancers.)
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The genotype frequencies of the ADH1C polymorphism in
different populations are shown in table 2 (20, 23, 25–30, 33,
38, 41–54). Neither the ADH1C*1 allele nor the ADH1C*2
allele was predominant among Caucasians; approximately
50–70 percent of these persons had the heterozygous
ADH1C*1/2 genotype. In contrast, the ADH1C*2 allele was
relatively uncommon among Asians, and ADH1C*2/2
homozygosity was rarely reported. The one African study
reported a predominance of ADH1C*1/1 homozygosity,
although the absence of Hardy-Weinberg equilibrium
suggests a possible misclassification of genotyping data (20).
Table 3 shows the genotype frequencies of ALDH2 in
various populations (24–36, 41, 55–59). Nearly all Cauca-
sians carried the functional ALDH2*1/1 genotype (24, 41).
Similar patterns were seen among populations from South-
east Asia and Oceania, as well as some indigenous popula-
tions in Alaska, Mexico, and Chile (24). In contrast, the
ALDH2*2 null allele was frequently observed in East Asian
populations, typically with 30 percent ALDH2*1/2 heterozy-
gosity and 5–10 percent ALDH2*2/2 homozygosity (24–34,
57–59). A similar pattern was also observed in an indigenous
Brazilian population (24). No information on African popu-
lations was available.
In summary, the fast metabolizing ADH1B*2 allele and
the null ALDH2*2 allele seem to be specific to Asian popu-
lations, whereas the ADH1C*2 allele is commonly observed
in Caucasian populations. Although data are lacking, it is
likely that most of the inherited variation in acetaldehyde
levels in Caucasians is determined by ADH1C, with minor
contributions from ADH1B and possibly a cytochrome P-
450 (CYP) gene, CYP2E1 (60). Conversely, it is likely that
inherited variation in acetaldehyde levels among Asians is
predominantly determined by ADH1B and ALDH.
Disease
Head and neck cancers are a related group of cancers that
involve the oral cavity, pharynx, and larynx (International
Classification of Diseases, Ninth Revision (ICD-9), codes
140–149 and 161). Cancer of the esophagus (ICD-9 code
150) is sometimes included as a head and neck cancer;
however, because of its mixed histology and etiology, with
adenocarcinoma predominating over squamous cell carci-
noma in some populations, it was excluded from this review.
The incidence of head and neck cancers varies widely
throughout the world (61). For example, the incidence of
oral cavity and pharyngeal cancer in men varies up to 35-fold
between high-risk areas such as Sommes, France (world age-
standardized incidence rate per 100,000 (ASR) = 43) and
low-risk areas such as The Gambia (ASR = 1) (61). For
women, oral cavity and pharyngeal cancer incidence rates
may vary up to 38-fold between high-risk areas such as
South Karachi, Pakistan (ASR = 19) and low-risk areas such
as Kangwa County, South Korea (ASR = 0.5) (61). In all
populations, rates in men exceed those in women by a factor
of 4–10. When subsites within the oral cavity and pharynx
are examined, cancer of the oropharynx and hypopharynx
account for as many cases as or more cases than cancer of the
oral cavity in high-risk European populations, while cancers
of the tongue, the floor of the mouth, and other parts of the
oral cavity represent the majority of cases in India and the
United States (61).
More than 90 percent of cancers of the larynx are squa-
mous cell carcinomas, and the majority originate from the
supraglottic and glottic regions of the organ (62). The inci-
dence of laryngeal cancer in men, including all histologic
types, is relatively high in southern and central Europe (Zara-
goza, Spain: ASR = 18; Lower Silesia, Poland: ASR = 13;
Croatia: ASR = 13), southern Brazil (Campinas, Brazil:
ASR = 7), Uruguay (Montevideo, Uruguay: ASR = 12), and
Argentina (Concordia, Argentina: ASR = 10) and among
Blacks in the United States (ASR = 10), while the lowest
rates are recorded in Southeast Asia (Beijing, China: ASR =
1.8; Hanoi, Vietnam: ASR = 1.5) and central Africa
(Kyadondo County, Uganda: ASR = 1.3) (61). The incidence
of laryngeal cancer in women is below 2 per 100,000 in most
populations. These rates have not changed markedly during
the last two decades.
Lifestyle factors.   The main risk factors for head and neck
cancer in Western countries are alcohol drinking and tobacco
smoking, which in individual studies have been found to
account for 75–90 percent of the disease (62, 63). The risk of
head and neck cancer increases rapidly with both the
frequency and the duration of tobacco and alcohol use, with
no evidence of any threshold effect for either. Most studies
appear to show increased risks for smokers on the order of 3-
to 10-fold relative to never smokers and increased risks for
heavy drinkers on the order of 2- to 9-fold relative to light-
to-moderate drinkers. The combined impact of tobacco
smoking (cigarettes/day) and alcohol consumption (drinks/
week) is greater than the sum of the individual effects of
these factors and may even exceed a multiplicative effect
(64, 65). The high incidence of head and neck cancer in parts
of Mediterranean Europe may be due to the higher risk asso-
ciated with the use of black as opposed to blond tobacco, as
well as local alcohol drinking habits (e.g., calvados
consumption in Normandy) (65). Areas of high head and
neck cancer incidence in non-Western populations are also
largely explained by local habits, such as betel quid chewing
in South Asia and consumption of very hot mate in South
America.
Dietary factors.   A diet that is deficient in fruits and vege-
tables is also a recognized risk factor for head and neck
cancer, accounting for possibly 10–15 percent of cases (66).
Increased risks have been found with decreasing consump-
tion of fresh fruits and vegetables, as well as vitamins A and
C. Conversely, it is possible that frequent dietary consump-
tion of salted meat and fish, as well as pickled vegetables,
may represent a risk factor. A topic that has received little
attention is the effect of alcohol or tobacco in conjunction
with a diet deficient in fruits and vegetables.
Human papillomavirus.   Benign lesions of the head and
neck, including laryngeal papillomas and oral verrucal papil-
lary lesions, illustrate the potential for human papillomavi-
ruses to infect squamous tissue of the head and neck and
raise the possibility that oncogenic human papillomaviruses
may be involved in the development of some head and neck
cancers (67). The most informative studies regarding head
and neck cancer have been based on a network of large
serum banks in Norway, Finland, and Sweden comprising
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approximately 900,000 subjects (68–70). In an analysis of
292 persons with oral, pharyngeal, or laryngeal cancer and
1,568 matched controls, an increased risk (odds ratio (OR) =
2.2, 95 percent confidence interval (CI): 1.4, 3.4) was
observed for human papillomavirus 16 seropositivity after
adjustment for cotinine levels. The largest series of head and
neck cancer cases investigated for human papillomavirus
DNA was a series of 253 US cases (71). Detection of human
papillomavirus was most common in the oropharynx (57
percent of oropharyngeal cases) and was moderately
frequent in the larynx (19 percent), oral cavity (12 percent),
and hypopharynx (10 percent).
Genetic susceptibility.   Given that the majority of heavy
drinkers and smokers do not develop head and neck cancer,
a genetic component for these cancers seems plausible.
Figure 2 illustrates a broad mechanism by which families of
genes may be involved in head and neck cancer. These could
include genes that may influence behavior, which might lead
to increased alcohol or tobacco consumption, as well as
phase I and phase II metabolizing genes (such as ADH,
ALDH, CYP, and N-acetyltransferase genes) that are likely to
be important in determining internal carcinogenic dose (72).
The subsequent development of DNA mutations, repair of
these errors, or cell apoptosis might also be regulated by
TABLE 1.   Genotype frequency of the ADH1B polymorphism, by geographic region
Region and study (ref. no.) Geographic 
area
Description 
of subjects Race/ethnicity
Hardy-
Weinberg 
p value
Genotype frequency (percentage)
Total no. of 
subjects 1/1 1/2 2/2 1/3 2/3 3/3
Africa
Iron et al., 1992 (20) Niger Not specified Black African 0.26 45 66.7 0.0 0.0 26.7 0.0 6.7
Viljoen et al., 2001 (21) South Africa Blood donors Khoisan-Caucasian 0.04 132 74.1 17.4 1.1 5.1 1.7 0.5
Americas
Thomasson et al., 1995 (22) United States College students, 
nonalcoholic
African-American 0.99 326 61.7 0.0 0.0 33.7 0.0 4.6
Wall et al., 2003 (23) United States Population-based, 
nonalcoholics
Native American 0.00 137 83.2 5.8 1.5 8.8 0.7 0.0
Goedde et al., 1992 (24) United States Not specified Alaskan Inuit 27 100.0 0.0 0.0
Brazil Caboclo 0.00 20 90.0 0.0 10.0
Chile Aurocanian 27 100.0 0.0 0.0
Mexico Mestizo 0.67 57 89.5 10.5 0.0
Asia
East Asia
Shen et al., 1997 (25) China Nonalcoholics Han 0.51 48 12.5 39.6 47.9
Korea Korean 0.41 50 6.0 46.0 48.0
Mongolia Mongolian 0.40 35 17.1 40.0 42.9
China Elunchun 0.11 37 32.4 59.5 8.1
Goedde et al., 1992 (24) China Not specified Chinese 0.37 86 8.1 47.7 44.2
Luu et al., 1995 (26) China Medical students, 
nonalcoholic
Chinese 0.53 273 7.7 37.4 55.0
Chao et al., 1997 (27) Taiwan Medical students, 
nonalcoholic
Taiwanese 0.60 100 6.0 51.0 53.0
Chen et al., 1996 (28) Taiwan Community center Han 0.16 63 0.0 30.2 69.8
Thomasson et al., 1991 (29) Taiwan Hospital staff, 
nonalcoholic
Chinese 0.81 47 6.4 40.4 53.2
Thomasson et al., 1994 (30) Taiwan Atayal 0.51 65 1.5 15.4 83.1
Goedde et al., 1992 (24) Korea Not specified Korean 0.90 177 4.0 31.1 65.0
Goedde et al., 1992 (24) Japan Not specified Japanese 0.84 32 15.6 50.0 34.4
Higuchi et al., 1996 (31) Japan Hospital staff Japanese 0.17 451 7.3 34.8 57.9
Maezawa et al., 1995 (32) Japan Not specified Japanese 0.53 60 3.3 36.7 60.0
Nakamura et al., 1996 (33) Japan Hospital staff, 
nonalcoholic
Japanese 0.00 97 3.1 55.7 41.2
Takeshita et al., 2000 (34) Japan Hospital Japanese 0.61 125 6.4 34.4 59.2
Table continues
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DNA repair genes or tumor suppressor genes (73). The effi-
ciency of these genes may vary strongly between individ-
uals, providing a further basis for differences in risk. Most
genetic studies of head and neck cancer have focused on
genes responsible for metabolizing potential carcinogens,
specifically phase I genes such as CYP2E1 and CYP1A1 and
phase II genes such as those of the glutathione S-transferase
and N-acetyltransferase families. Inconclusive evidence for
associations of head and neck cancer with the null genotypes
of the glutathione S-transferase M1 and T1 genes was
reported in a prior Human Genome Epidemiology review
(74). An overview of CYP and N-acetyltransferase polymor-
phisms in the risk of head and neck cancer also suggested no
consistent associations (72).
Even though alcohol is a major risk factor for head and
neck cancer, the mechanism by which it causes the disease is
unclear, especially since pure ethanol does not act as a
carcinogen in experimental models (75). One possibility is
that the carcinogenic effect of alcoholic beverages is due to
acetaldehyde, the initial metabolite of ethanol. Acetaldehyde
is a recognized mutagen and animal carcinogen, although
specific evidence that it is a cause of head and neck cancer in
humans has not been established. However, given that fast
alcohol metabolizers will have the greatest peak exposure to
TABLE 1.  Continued
Region and study (ref. no.) Geographic 
area
Description 
of subjects Race/ethnicity
Hardy-
Weinberg
 p value
Genotype frequency (percentage)
Total no. of 
subjects 1/1 1/2 2/2 1/3 2/3 3/3
Southeast Asia
Goedde et al., 1992 (24) Philippines Not specified Filipino 0.24 57 19.3 40.4 40.4
Malaysia Malaysian 0.92 65 16.9 47.7 35.4
Thailand Thai 0.48 111 45.9 41.4 12.6
Osaka et al., 2003 (35) Thailand Population-based Thai 0.72 153 29.4 51.0 19.6
Boonyaphiphat et al., 
2002 (36)
Thailand Hospital, 
nonalcoholic
Thai 0.03 261 36.0 53.3 10.7
Iron et al., 1992 (20) Vietnam Not specified Vietnamese 0.90 42 59.5 35.7 4.8
Goedde et al., 1992 (24) India Not specified Indian 0.00 167 85.0 10.2 4.8
Europe
Rodrigo et al., 1999 (37) Spain Not specified Caucasian 0.31 200 86.5 13.5 0.0
Borras et al., 2000 (38) Spain Hospital staff and 
blood donors, 
nonalcoholic
Caucasian 0.73 37 89.2 10.8 0.0
France Caucasian 40 100.0 0.0 0.0
Germany Caucasian 0.94 41 97.6 2.4 0.0
Poland Caucasian 0.90 66 97.0 2.9 0.0
Sweden Caucasian 0.81 40 93.0 7.0 0.0
Goedde et al., 1992 (24) Sweden Not specified Caucasian 0.96 90 98.9 1.1 0.0
Germany Caucasian 0.52 233 91.8 8.2 0.0
Finland Caucasian 0.91 85 97.6 2.4 0.0
Hungary Caucasian 0.55 115 89.6 10.4 0.0
Ogurtsov et al., 2001 (39) Russia Not specified Russian 0.16 50 30 58 12
Middle East
Goedde et al., 1992 (24) Turkey Not specified 0.67 44 77.3 20.5 2.3
Oceania
Amadeo et al., 2000 (40) Tahiti Nonalcoholics Polynesian 0.96 21 38.1 47.6 14.3
Chambers et al., 2002 (41) New Zealand Blood donors Polynesian 0.62 56 30.4 46.4 23.2
Asian 0.01 19 15.8 15.8 68.4
Amadeo et al., 2000 (40) Tahiti Nonalcoholics Polynesian-Chinese 0.87 11 9.1 45.5 45.5
Polynesian-
Caucasian
0.25 23 26.1 60.9 13.0
Chambers et al., 2002 (41) New Zealand Blood donors Caucasian 0.90 17 94.1 5.9 0.0
Goedde et al., 1992 (24) Papua New 
Guinea
Not specified Papua New Guinean 0.03 204 87.7 10.8 1.5
Australia Aborigine 0.67 22 45.5 40.9 13.6
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TABLE 2.   Genotype frequency of the ADH1C polymorphism, by geographic region
Region and study (ref. no.) Geographic 
area
Description 
of subjects Race/ethnicity
Hardy-Weinberg
 p value
Genotype frequency (percentage)
Total no. of 
subjects 1/1 1/2 2/2
Africa
Iron et al., 1992 (20) Niger Not specified Black African 0.00 45 75.6 0.0 24.4
Americas
Harty et al., 1997 (42) Puerto Rico Population-based Caucasian, Black, 
Mestizo, other 
0.80 146 38.4 50.0 12.5
Olshan et al., 2001 (43) United States Hospital African-American, 
Caucasian
0.89 194 38.7 47.4 13.9
Schwartz et al., 2001 (44) United States Population-based Caucasian, African-
American, other
0.01 541 36.4 43.2 20.3
Freudenheim et al., 1999 (45) United States Population-based Caucasian 0.85 356 34.6 48.9 16.6
Sturgis et al., 2001 (46) United States Hospital Non-Hispanic 
Caucasian
0.11 575 31.3 52.5 16.5
Chen et al., 2001 (47) United States Population-based 94% Caucasian 0.34 1,113 38.3 46.1 15.6
Hines et al., 2000 (48) United States Population-based, 
nurses
85% Caucasian 0.85 621 34.0 48.3 17.7
Hines et al., 2001 (49) United States Population-based, 
physicians
93% Caucasian 0.47 770 36.2 46.9 16.9
Segal, 1999 (50) United States Population-based Yupik Inuit 0.00 69 29.0 31.9 39.1
Wall et al., 2003 (23) United States Population-based, 
nonalcoholics
Native American 0.04 137 69 49 19
Asia
Shen et al., 1997 (25) China Nonalcoholics Han 0.21 48 85.4 12.5 2.1
Korea Korean 0.00 50 86.5 9.6 0.0
Mongolia Mongolian 0.51 35 80.0 20.0 0.0
China Elunchun 0.34 37 73.0 27.0 0.0
Luu et al., 1995 (26) China Medical students, 
nonalcoholic
Chinese 0.06 273 79.9 20.1 0.0
Chao et al., 1997 (27) Taiwan Medical students, 
nonalcoholic
Taiwanese 0.34 100 88.0 11.0 1.0
Chen et al., 1996 (28) Taiwan Community center Han 0.69 62 90.3 9.7 0.0
Thomasson et al., 1994 (30) Taiwan Not specified Atayal 0.95 63 98.4 1.6 0.0
Thomasson et al., 1991 (29) Taiwan Hospital staff, 
nonalcoholic
Chinese 0.70 47 89.4 10.6 0.0
Nakamura et al., 1996 (33) Japan Hospital staff, 
nonalcoholic
Japanese 0.67 97 91.7 8.2 0.0
Iron et al., 1992 (20) Vietnam Not specified Vietnamese 0.00 46 84.8 2.2 13.0
Europe
Borras et al., 2000 (38) Spain Hospital staff and 
blood donors, 
nonalcoholic
Caucasian 0.03 37 18.9 67.6 13.5
France Caucasian 1.00 40 37.5 47.5 15.0
Germany Caucasian 0.86 41 22.0 51.2 26.8
Poland Caucasian 0.75 66 28.8 51.5 19.7
Sweden Caucasian 0.80 40 40.0 45.0 15.0
Bouchardy et al., 2000 (51) France Hospital Caucasian 0.04 167 36.5 41.3 22.2
Coutelle et al., 1997 (52) France Alcoholics Caucasian 0.01 38 18.4 71.5 10.5
Zavras et al., 2002 (53) Greece Hospital Caucasian 0.45 99 49.5 39.4 11.1
Grove et al., 1998 (54) United Kingdom Hospital staff Caucasian 0.44 121 34.7 51.2 14.0
Oceania
Chambers et al., 2002 (41) New Zealand Blood donors Caucasian 1.00 35 34 49 17
Asian 0.72 20 85 15 0
Polynesian 0.23 53 58 40 2
ADH and Head and Neck Cancer: A HuGE Review   7
 Am J Epidemiol   2004;159:1–16
TABLE 3.   Genotype frequency of the ALDH2 polymorphism, by geographic region
Region and study (ref. no.) Geographic area Description of 
subjects Race/ethnicity
Hardy-Weinberg
 p value
Genotype frequency (percentage)
Total no. of 
subjects 1/1 1/2 2/2
Americas
Goedde et al., 1992 (24) Brazil Not specified Caboclo 0.31 23 65.2 34.8 0.0
Chile Aurocanian 7 100.0 0.0 0.0
Mexico Mestizo 61 100.0 0.0 0.0
United States Alaskan Inuit 27 100.0 0.0 0.0
Gill et al., 1997 (55) United States Hospital Native American 105 100.0 0.0 0.0
McCarthy et al., 2000 (56) United States College students Asian American 0.03 171 53.8 43.3 2.9
Asia
East Asia
Shen et al., 1997 (25) China Nonalcoholics Han 0.67 48 58 38 4
Korea Korean 0.03 50 34 60 6
Mongolia Mongolian 0.58 35 83 17 0
China Elunchun 0.09 37 86 11 3
Goedde et al., 1992 (24) China Not specified Chinese 0.38 132 69.7 28.8 1.5
Luu et al., 1995 (26) China Medical students, 
nonalcoholic
Chinese 0.03 273 52.7 43.2 4.0
Chao et al., 1997 (27) Taiwan Medical students, 
nonalcoholic
Taiwanese 0.89 100 50.0 41.0 9.0
Thomasson et al., 1991 (29) Taiwan Hospital staff, 
nonalcoholics
Chinese 0.31 47 52 36 12
Chen et al., 1996 (28) Taiwan Community center Han 0.69 63 57.1 38.1 4.8
Thomasson et al., 1994 (30) Taiwan Not specified Atayal 0.05 65 90.9 7.6 1.5
Goedde et al., 1992 (24) Korea Not specified Korean 0.60 218 71.6 2.7 1.8
Lee et al., 1997 (57) Korea Blood donors Korean 0.57 481 70.9 26.2 2.9
Goedde et al., 1992 (24) Japan Not specified Japanese 0.14 53 54.7 43.4 1.9
Higuchi et al., 1996 (31) Japan Hospital staff Japanese 0.42 451 58.5 35.0 6.4
Maezawa et al., 1995 (32) Japan Not specified Japanese 0.25 60 56.7 33.3 10.0
Nakamura et al., 1996 (33) Japan Hospital staff, 
nonalcoholics
Japanese 0.04 97 59.8 29.9 10.3
Takeshita et al., 2000 (34) Japan Hospital Japanese 0.69 125 52.0 39.2 8.8
Fujii et al., 1998 (58) Japan Not specified Japanese 0.77 297 59.9 35.4 4.7
Kamino et al., 2000 (59) Japan Hospital Japanese 0.04 447 62.6 60.9 6.5
Southeast Asia
Goedde et al., 1992 (24) Philippines Not specified Filipino 0.24 86 98.8 1.2 0.0
Malaysia Malaysian 0.76 73 93.2 6.8 0.0
Thailand Thai 0.58 111 90.1 9.9 0.0
Boonyaphiphat et al., 2002 (36) Thailand Hospital, 
nonalcoholics
Thai 0.02 261 82.4 15.3 2.3
Osaka et al., 2003 (35) Thailand Population-based Thai 0.61 153 92.2 7.8 0.0
Goedde et al., 1992 (24) India Not specified Indian 0.00 179 96.6 2.8 0.5
Europe
Goedde et al., 1992 (24) Germany Not specified Caucasian 193 100.0 0.0 0.0
Sweden Caucasian 99 100.0 0.0 0.0
Finland Caucasian 100 100.0 0.0 0.0
Hungary Caucasian 0.89 117 97.4 2.6 0.0
Middle East
Goedde et al., 1992 (24) Turkey Not specified Caucasian 57 100.0 0.0 0.0
Oceania
Chambers et al., 2002 (41) New Zealand Blood donors Caucasian 14 100 0 0
Asian 0.57 14 64 29 7
Polynesian 55 100 0 0
Goedde et al., 1992 (24) Papua New Guinea Not specified Papua New Guinean 0.95 242 99.2 0.8 0.0
Australia Aborigine 37 100.0 0.0 0.0
8   Brennan et al.
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acetaldehyde, it has been hypothesized that possession of
ADH1B and ADH1C genotypes encoding for fast alcohol
metabolism will confer an increased risk of head and neck
cancer. Similarly, the null ALDH2*2 allele may contribute to
an increased level of acetaldehyde and act as a risk factor for
head and neck cancer. Therefore, a prime hypothesis is that
possession of the ADH1C*1, ADH1B*2, and ALDH*2
alleles, either singularly or in combination, will confer an
increased risk of head and neck cancer among persons who
consume alcohol. Although ethanol and water are the main
components of alcoholic beverages, known carcinogens
such as nitrosamines can also be present as contaminants
(75). Polymorphisms in the genes that metabolize carcino-
genic contaminants may also play a role in carcinogenesis.
Associations and interactions
To examine the association between ADH1B, ADH1C, and
ALDH2 polymorphisms and head and neck cancer, we
undertook a pooled analysis of all relevant studies. We
conducted a MEDLINE search to identify all studies
published before December 2002, without restriction on
language, using the keywords “ADH2,” “ADH3,” “ADH1B,”
“ADH1C,” and “ALDH2.” We subsequently reviewed the
reference lists of all published studies to confirm that all rele-
vant studies had been identified. As we noted above, the
studies were restricted to oral cavity, pharyngeal, and laryn-
geal cancers. The results of this search brought the total
number of published case-control studies on head and neck
cancer to 10: seven studies on ADH1C (42–44, 46, 51–53),
two studies on ALDH2 (76, 77), and one study on both
ADH1B and ALDH2 (78).
Given the benefits of pooling original data from a series of
studies over meta-analysis of published results (79), we
contacted the investigators from the seven groups that had
conducted studies on ADH1C and asked them to provide
their original data on tobacco and alcohol exposure and
genotype. All seven groups of investigators agreed to this
request and provided data on the following variables: 1) head
and neck cancer subsite according to ICD-9 code or Interna-
tional Classification of Diseases for Oncology three-digit
code; 2) age at diagnosis (or on the corresponding date for
controls); 3) sex; 4) ADH1C genotype; 5) tobacco smoking
status (never/ex-/current); and 6) alcohol consumption status
(never/ex-/current). Institutional review board approval had
been obtained for each of the individual studies, and personal
identifiers were not included in the pooled data. The defini-
tion of current smoking and current drinking was generally
taken as smoking or drinking 1 year prior to interview. For
the data of Olshan et al. (43), smoking status (ex- vs. current)
had to be determined from smoking duration, under the
assumption that subjects had started smoking at age 20 years.
A similar assumption was made for determination of current
alcohol consumption in the data of Zavras et al. (53). These
assumptions are likely to have led to underestimation of the
numbers of current smokers and current drinkers in those
two studies, respectively, since smokers in the study by
Olshan et al. (43) and drinkers in the study by Zavras et al.
(53) who commenced their use before the age of 20 years
would have been classified as ex-smokers and ex-drinkers.
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Information on amount of alcohol consumption among
current drinkers was available for all studies except one (52).
Subsequently, the number of drinks consumed per week
among current drinkers was stratified into three groups: 1–
19, 20–59, and ≥60. All subjects in the one study that was
restricted to alcoholics (46), which did not provide actual
numbers of drinks, were assumed to have consumed 60 or
more drinks per week. The cutoff points for the number of
drinks per week among current drinkers were chosen thus,
because “60 or more” refers to the alcoholics in one study
(46), “0.1–19.9” equates approximately to recommended
levels for men, and “20–59.9” is the intermediate level
between the two. The inclusion criteria for cancer subsites
consisted of ICD-9 codes 141 and 143–145 for oral cancer,
ICD-9 codes 146, 148, and 149 for pharyngeal cancer, and
ICD-9 code 161 for laryngeal cancer. ICD-9 code 140 (lip
cancer) was included in one study (43) that had two cases.
ICD-9 code 142 (salivary gland) and ICD-9 code 147
(nasopharynx) were excluded.
Hardy-Weinberg equilibrium for the three ADH1C geno-
types was assessed separately for both cases and controls in
each study. A priori, it would be expected that the ADH1C
genotype frequencies among controls would be in Hardy-
Weinberg equilibrium, though not necessarily among cases
(80). Heterogeneity in genotype frequencies between the
seven studies was analyzed among the controls using the
Kruskal-Wallis test. Subsequently, odds ratios and 95
percent confidence intervals were calculated for possession
of one or two fast ADH1C*1 alleles compared with the slow
ADH1C*2/2 genotype, both overall and for head and neck
cancer subsites, as well as after stratifying for alcohol
consumption status. Odds ratios were estimated using
unconditional logistic regression, adjusting where necessary
for age, sex, and study. Additional adjustment for tobacco
use did not materially affect the results. The test for trend in
possessing 0, 1, or 2 ADH1C*1 alleles was also calculated.
We assessed departures from multiplicative interaction by
including interaction terms in the appropriate logistic regres-
sion models and comparing the models by means of a likeli-
hood ratio test (81).
Given that only one study was identified for head and neck
cancer and ADH1B and three studies were identified for
ALDH2 (one of which was conducted among alcoholics),
pooling of the original data from these studies was deemed
unnecessary, and the published results are presented sepa-
rately.
RESULTS
Pooled analysis of ADH1C studies
Selected characteristics of the seven studies on ADH1C
are presented in table 4. The total pooled data set included
1,325 cases and 1,760 controls. The 1,325 cases included
758 cancers of the oral cavity (57 percent), 292 pharyngeal
cancers (22 percent), and 261 laryngeal cancers (20 percent).
An overall departure from Hardy-Weinberg equilibrium
was observed for the ADH1C genotype among the cases (p =
0.03), though not among the controls (p = 0.9). When it was
analyzed by study, this excess was significant for only one
study (51) (p = 0.034), though the differences between
observed and expected frequencies for both homozygous
genotypes were less than 5 percent. Although no overall
departure from Hardy-Weinberg equilibrium was observed
among the controls, statistically significant differences in
study-specific frequencies were observed. For Schwartz et
al. (44), the differences between observed and expected
homozygous genotypes were less than 5 percent, whereas for
Coutelle et al. (52), a substantial excess of the heterozygous
ADH1C*1/2 genotype was observed (71 percent observed
vs. 49.7 percent expected) (p = 0.033). The variation in
control genotype frequencies among the seven studies was of
borderline significance (p = 0.05).
Table 5 presents the associations between head and neck
cancer and ADH1C genotype, overall and by drinking cate-
gory. No significantly increased risk of head and neck cancer
was observed for possession of the ADH1C*1/2 heterozy-
gous genotype (OR = 1.00, 95 percent CI: 0.81, 1.23) or the
ADH1C*1/1 homozygous genotype (OR = 1.14, 95 percent
CI: 0.92, 1.41). Similarly, when the analysis was conducted
by subsite, there was no evidence of any increased risk for
possession of either one or two fast metabolizing alleles, or
any evidence of a dose response with increasing number of
fast alleles for cancers of the pharynx or larynx. The risk of
oral cancer may be increased by the ADH1C*1/1 genotype
(OR = 1.27, 95 percent CI: 0.97, 1.66). Similarly, when data
were stratified by drinking status, there was no significant
evidence for differing effects of ADH1C genotype between
current, former, and never drinkers (p for interaction > 0.20).
The individual results of the six studies with information
on amount of alcohol consumed are presented in table 6. One
study (42) observed a large increase in risk for the
ADH1C*1/1 genotype among heavy drinkers (≥60 drinks/
week), based on 39 cases and six controls. Two other studies
FIGURE 2. The potential role of genetic susceptibility in the pathway to head and neck cancer.
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(51, 52) that included a greater number of cases and controls
who were heavy drinkers did not observe this association.
Heterogeneity was observed between individual studies in
the upper two categories of current drinkers, but interpreta-
tion of findings from the individual studies is limited by the
small number of subjects in these categories. Pooled analysis
of these six studies showed some evidence of interaction
between ADH1C genotype and amount of alcohol consumed
(p = 0.039); this appeared to be primarily due to an increased
risk among heavy drinkers (≥60 drinks per week) associated
with the ADH1C*1/1 genotype in the studies by Harty et al.
(42) and Olshan et al. (43).
ADH1B study
One case-control study on head and neck cancer and the
ADH1B genotype was identified (78) (table 7). The study
included 34 alcoholic male patients with squamous cell
carcinomas of the head and neck as cases and 526 male alco-
holics without cancer as controls. An overall odds ratio of
6.68 (95 percent CI: 2.81, 15.90) was observed for head and
neck cancer and ADH1B*1/1 in comparison with *1/2 or
*2/2 after adjustment for age, daily alcohol consumption,
amount of cigarette smoking, and the ALDH2 genotype.
These findings, which were significant, were the inverse of
what was expected on the basis of the known function of
ADH1B. Odds ratios from this study for sites within the head
and neck were 5.48 (95 percent CI: 1.77, 17.0) for oropha-
ryngeal cancer and 6.57 (95 percent CI: 1.62, 21.3) for laryn-
geal cancer (table 7).
ALDH2 studies
Three Japanese studies have investigated the relation
between the ALDH2 genotype and oral, pharyngeal, and
laryngeal cancers (76–78) (table 7). The study of alcoholics
by Yokoyama et al. (78) identified a strong but imprecise
relative risk associated with the heterozygous genotype as
compared with the fully functional ALDH2*1/1 genotype for
oropharyngeal cancer (OR = 20.83, 95 percent CI: 6.62,
65.5). A case-control study of 114 oral and pharyngeal
cancer cases and 33 hospital controls reported an odds ratio
of 2.9 (95 percent CI: 1.1, 7.8) for ALDH2 heterozygosity
relative to the fully functional ALDH*1/1 homozygosity
(77). A third case-control study of 92 oral cancer cases and
147 hospital controls identified no association for either the
nonfunctional genotype or the heterozygous genotype (76).
These results suggest a possibly increased risk of head and
neck cancer associated with possessing one inactive
ALDH2*2 allele but not two inactive alleles.
TABLE 5.   Results of pooled analysis of data from seven case-control studies on the association of the ADH1C genotype and alcohol 
consumption with head and neck cancer
* Results were adjusted for age, sex, study center, and alcohol drinking status.
† OR, odds ratio; CI, confidence interval.
Type of head/neck cancer 
and ADH1C genotype
Overall results*
Alcohol drinking status
p for 
interaction
Never drinkers Ex-drinkers Current drinkers
No. of 
cases/
controls
OR† 95% CI†
No. of 
cases/
controls
OR 95% CI
No. of 
cases/
controls
OR 95% CI
No. of 
cases/
controls
OR 95% CI
All types
2/2 223/304 1.00 20/70 1.00 50/57 3.11 1.64, 5.90 153/177 2.85 1.62, 5.00 0.223
1/2 583/831 1.00 0.81, 1.23 85/207 1.36 0.78, 2.40 127/175 2.59 1.48, 4.54 371/449 2.82 1.65, 4.82
1/1 519/625 1.14 0.92, 1.41 73/174 1.36 0.77, 2.42 147/120 4.08 2.32, 7.19 299/330 2.94 1.71, 5.05
Dose response p = 0.154
Oral
2/2 110/304 1.00 12/70 1.00 30/57 3.07 1.39, 6.76 68/177 2.54 1.25, 5.18 0.160
1/2 339/831 1.13 0.87, 1.47 50/207 1.31 0.64, 2.66 69/175 2.40 1.19, 4.86 220/449 3.18 1.62, 6.21
1/1 309/625 1.27 0.97, 1.66 50/174 1.45 0.71, 2.95 92/120 4.15 2.06, 8.39 167/330 3.04 1.54, 5.97
Dose response p = 0.067
Pharyngeal
2/2 64/293 1.00 4/62 1.00 12/55 3.25 0.98, 10.8 48/176 4.01 1.36, 11.8 0.515
1/2 118/792 0.68 0.48, 0.95 16/187 1.27 0.41, 3.95 33/162 2.88 0.97, 8.58 69/443 2.26 0.78, 6.52
1/1 110/576 0.89 0.63, 1.26 11/150 1.15 0.35, 3.76 30/103 4.12 1.37, 12.4 69/323 3.12 1.08, 9.05
Dose response p = 0.881
Laryngeal
2/2 46/163 1.00 4/53 1.00 8/29 2.80 0.74, 10.5 34/81 2.26 0.72, 7.06 0.679
1/2 120/488 0.99 0.65, 1.50 19/148 1.45 0.46, 4.56 21/106 2.09 0.66, 6.63 80/234 2.24 0.76, 6.64
1/1 95/323 1.17 0.76, 1.80 12/117 1.12 0.33, 3.74 22/65 3.51 1.10, 11.2 61/141 2.62 0.87, 7.85
Dose response p = 0.387
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DISCUSSION
Large differences in genotype distribution were observed
between different ethnic groups for all three ADH and
ALDH genes, with the fast metabolizing ADH1B*2 and
ADH1C*1 alleles and the nonfunctional ALDH2*2 allele
being seen more commonly in Asian populations. Further-
more, while the few existing studies suggest an increased
risk of head and neck cancer for the ALDH2*1/2 and
ADH1B*1/1 genotypes, the combined analysis of all seven
published case-control studies on ADH1C fast alleles does
not provide consistent evidence for a major role of this
genetic variant in head and neck cancer overall. However,
among current drinkers, there was evidence of an interaction
between the ADH1C*1/1 genotype and high levels of
alcohol consumption.
Of the two initial studies (42, 52), which supported a role
for ADH1C in head and neck cancer, the study by Coutelle et
al. (52) differed from the other six studies because it was
restricted to a small group of alcoholic men. This selection
of alcoholics may explain the lack of Hardy-Weinberg
equilibrium in the control population, where a surplus of
ADH1C*2/1 heterozygotes was observed at the expense of
ADH1C*1/1 homozygotes; it is possible that ADH1C*1/1
homozygotes are less likely to become alcoholic because of
the side effects associated with rapid ethanol metabolism
(82). In the original analysis of Coutelle et al. (52),
ADH1C*1/1 homozygotes were compared with *1/2
heterozygotes and 2/2 homozygotes combined, although the
increased risk for ADH1C*1/1 is less apparent when *2/2
homozygotes are taken as the reference category. Pooled
TABLE 6.   Association of the ADH1C genotype and alcohol consumption with head and neck cancer among current drinkers*
* Includes current drinkers for whom the actual number of drinks consumed per week was known; does not include data from the study by Sturgis et al. (46).
† Results were adjusted for age, sex, and alcohol consumption.
‡ OR, odds ratio; CI, confidence interval.
§ Results were adjusted for age, sex, and study center.
Study (ref. no.) and 
ADH1C genotype
Current drinkers†
Alcohol consumption (no. of drinks per week)
0 (never drinkers) 0.1–19.9 20–59.9 ≥60
No. of 
cases/
controls
OR‡ 95% CI‡
No. of 
cases/
controls
OR 95% CI
No. of 
cases/
controls
OR 95% CI
No. of 
cases/
controls
OR 95% CI
No. of 
cases/
controls
OR 95% CI
Coutelle et al., 1997 
(52)
2/2 6/4 1.00 6/4 1.00
1/2 14/27 0.67 0.11, 4.08 14/27 0.67 0.11, 4.08
1/1 19/7 2.69 0.39, 18.6 19/7 2.69 0.39, 18.6
Harty et al., 1997 (42)
2/2 9/7 1.00 1/5 1.00 1/4 1.25 0.05, 29.6 6/2 20.0 1.16, 345 2/1 13.8 0.48, 394
1/2 29/34 0.66 0.18, 2.42 10/21 2.60 0.26, 25.9 6/20 1.95 0.17, 22.6 8/10 5.57 0.45, 69.0 15/4 25.9 1.95, 344
1/1 36/26 1.08 0.29, 4.03 6/15 2.13 0.20, 22.5 4/19 1.42 0.11, 17.9 10/6 11.4 0.91, 143 22/1 144 6.53, 3193
Bouchardy et al., 2000 
(51)
2/2 50/32 1.00 2/2 1.00 3/4 0.76 0.06, 9.02 21/18 1.14 0.15, 8.98 26/10 2.54 0.31, 20.6
1/2 77/56 0.94 0.52, 1.69 11/6 1.76 0.19, 15.9 6/9 0.61 0.07, 5.67 38/33 1.09 0.14, 8.19 33/14 2.31 0.30, 18.1
1/1 69/41 1.08 0.59, 2.00 7/15 0.45 0.05, 3.94 3/8 0.34 0.03, 3.67 29/23 1.19 0.15, 9.14 37/10 3.66 0.46, 29.4
Zavras et al., 2002 (53)
2/2 1/1 1.00 3/8 1.00 1/1 2.38 0.11, 53.1
1/2 12/6 2.35 0.08, 69.6 11/20 1.42 0.30, 6.57 4/3 5.38 0.65, 44.6 3/3 3.47 0.39, 30.8 5/0
1/1 10/7 2.02 0.07, 59.0 17/24 1.92 0.44, 8.50 4/4 2.84 0.40, 19.9 3/3 3.84 0.43, 34.4 3/0
Olshan et al., 2001 (43)
2/2 10/8 1.00 3/12 1.00 4/7 2.71 0.44, 16.9 2/1 11.0 0.58, 208 4/0
1/2 36/27 0.73 0.19, 2.74 13/45 0.94 0.22, 4.03 17/22 2.45 0.56, 10.6 10/5 7.82 1.35, 45.4 9/0
1/1 43/27 0.77 0.21, 2.86 15/34 1.68 0.39, 7.26 15/21 2.38 0.54, 10.5 17/5 12.0 2.23, 64.6 11/1 42.5 3.61, 499
Schwartz et al., 2001 
(44)
2/2 44/86 1.00 1/4 1.00 28/80 1.64 0.17, 15.5 10/6 9.09 0.79, 104 6/0
1/2 120/173 1.32 0.84, 2.10 6/18 1.59 0.15, 17.3 76/153 2.41 0.26, 22.2 33/17 10.1 1.02, 99.6 11/3 19.2 1.49, 248
1/1 76/154 1.08 0.66, 1.75 9/18 2.29 0.22, 23.9 52/146 1.75 0.19, 16.2 18/6 15.8 1.43, 175 6/2 16.4 1.06, 253
Overall§
2/2 120/138 1.00 10/31 1.00 37/96 1.43 0.62, 3.32 39/27 6.29 2.53, 15.6 44/15 16.4 6.09, 44.0
1/2 288/323 1.04 0.75, 1.43 51/110 1.46 0.66, 3.24 109/207 1.94 0.89, 4.26 92/68 5.40 2.39, 12.2 87/48 12.5 5.24, 30.0
1/1 253/262 1.10 0.79, 1.54 54/106 1.65 0.75, 3.66 78/198 1.43 0.65, 3.16 77/43 6.97 3.01, 16.1 98/21 29.8 11.8, 75.4
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analyses of the association between ADH1C*1/1 and head
and neck cancer were also conducted after exclusion of the
Coutelle et al. data, but the results did not change materially.
In the study by Harty et al. (42), while no overall associa-
tion was seen for ADH1C, a 10-fold greater risk of oropha-
ryngeal cancer was observed among heavy drinkers for
ADH1C*1/1 homozygotes as compared with *2/2 homozy-
gotes (p = 0.04); this is similar to the results shown in table
6, which used a slightly different cutoff point to define the
heaviest drinkers. However, this comparison was based on
very small numbers of subjects, leading to unstable esti-
mates. In addition, the comparison of cases in the interme-
diate alcohol consumption group (15–56 drinks per week in
the original analysis) showed an opposite association, with a
twofold higher risk for the ADH1C*2/2 genotype as opposed
to *1/1. In the absence of any association with ADH1C*1/1
among intermediate alcohol drinkers, and with the benefit of
hindsight from five additional studies, it is possible that these
patterns in the study by Harty et al. represented a chance
finding.
Of the subsequent five studies (43, 44, 46, 51, 53), only
one had a large number of heavy-drinker cases and controls
(51), allowing possible replication of these findings in heavy
drinkers, but no significant association was observed. Also
of interest is the fact that two of these five studies suggested
a greater increase in risk with increasing alcohol consump-
tion with the ADH1C*2 allele, though the reasons for this are
unclear (44, 53).
While it is unlikely that the ADH1C*1 allele has a major
effect on risk of head and neck cancer, a more moderate
association cannot be ruled out by our analysis (e.g., a 40
percent increase in overall risk or a 100 percent increase
among heavy drinkers). A 40 percent increase in risk for a
genotype that is present in one third of the population would
still result in a population attributable risk of approximately
12 percent for all head and neck cancers and a population
attributable risk of 25 percent among heavy drinkers.
Potential limitations of the pooled analysis include publi-
cation bias and population admixture. The seven case-
control studies were identified from published studies; thus,
publication bias could potentially have led to bias away from
the null through the inclusion of more studies with positive
findings. However, the overall null results from our pooled
analysis suggested that positive studies were not overrepre-
sented. In extreme situations, population admixture can lead
to confounding. Three of the case-control studies included
persons of different races (42–44). However, when we tested
for Hardy-Weinberg equilibrium among our controls, depar-
ture from Hardy-Weinberg equilibrium was not detected,
which suggests that population admixture may not have been
a major drawback. Furthermore, since the studies in the
pooled analysis were mostly studies of Caucasians and the
genotype distribution for the ADH1C polymorphism differs
by race, the risk estimates may only be generalizable to the
Caucasian population.
Regarding ADH1B, the increased risk of head and neck
cancer for ADH1B*1/1 (the slow genotype) in the one study
that tested for this association was contrary to the hypothesis
that fast metabolism of alcohol would lead to increased peak
acetaldehyde exposure and therefore greater risk. With the
use of alcoholic controls, there is a possibility that this odds
ratio was underestimated. However, this association may
simply reflect residual confounding by alcohol consumption.
Similar to the case among ALDH2*2/2 carriers, alcohol
consumption among persons who possess the ADH1B*2/2
genotype is likely to be substantially lower than that in the
rest of the population because of the occurrence of a toxic
reaction. Indeed, the one study on ADH1B conducted in the
Japanese population did not adjust for alcohol consumption,
though all participants were alcohol drinkers (78). Similarly,
for ALDH2, an increased risk was not observed for the
nonfunctional ALDH2*2/2 genotype. This may represent an
absence of alcohol consumption or very low consumption
among such persons. These findings point to the necessity
for careful control of alcohol consumption or stratification
by alcohol consumption in the analyses in genetic studies on
ADH1B and ALDH2. However, an increased risk was
observed for the semifunctional ALDH2*1/2 genotype in
two of the three studies that investigated this (77, 78). Such
a finding is consistent with an increased risk due to ineffi-
TABLE 7.   Association of the ADH1B and ALDH2 genotypes with head and neck cancer
* OR, odds ratio; CI, confidence interval.
† Alcoholic subjects.
‡ Adjusted for alcohol consumption.
Study (ref. no.) Genotype
Oral/pharyngeal cancer Laryngeal cancer
No. of cases/
controls OR* 95% CI*
No. of cases/
controls OR 95% CI
Yokoyama et al., 2001 (78)† ADH1B
1/1 vs. 1/2 or 2/2‡ 16/526 5.48 1.77, 17.0 18/526 6.57 1.62, 21.3
ALDH2
Katoh et al., 1999 (76) 2/2 vs. 1/1‡ 92/147 0.35 0.57, 2.17
1/2 vs. 1/1‡ 1.18 0.65, 2.13
Nomura et al., 2000 (77) 1/2 vs. 1/1 114/33 2.9 1.1, 7.8
Yokoyama et al., 2001 (78)† 1/2 vs. 1/1‡ 16/526 20.83 6.62, 65.49 18/526 28.92 8.66, 96.6
14   Brennan et al.
 Am J Epidemiol   2004;159:1–16
cient acetaldehyde metabolism and increased local exposure
to acetaldehyde. Since the reviews on ADH1B and ALDH2
included only Japanese studies, these results may be more
generalizable to the ethnic Asian population.
Concerning future studies on the role of ADH and ALDH
genes in head and neck cancer, several improvements over
previous studies can be recommended. Larger studies that
accurately measure the association with individual genes in
particular subgroups (e.g., defined by alcohol consumption
or ethnicity) and that incorporate joint analysis of relevant
ADH and ALDH genes simultaneously, as well as other
genes that may be involved in alcohol metabolism (such as
CYP2E1), are necessary. Mechanistic studies would be of
much use for clarifying the role of individual ADH and
ALDH genes in acetaldehyde exposure, including an assess-
ment of combinations of these genes. Also of interest would
be an assessment of the relation of acetaldehyde levels with
different patterns of alcohol consumption, including binge
drinking and moderate chronic consumption. The role of
ADH and ALDH genes should also be assessed with respect
to intermediate markers, including acetaldehyde adducts in
head and neck tissue. Finally, given the relative rarity of
head and neck cancers at any particular study center, these
considerations suggest the potential for the organization of a
consortium of investigators conducting studies in this field.
Laboratory tests
Methods of genotyping for the ADH1B and ADH1C poly-
morphisms (83, 84) and the ALDH2 polymorphism (85) by
means of the polymerase chain reaction and restriction frag-
ment length polymorphism techniques have been described
previously.
Population testing
No studies on the effectiveness or efficacy of genetic
testing for ADH1B, ADH1C, or ALDH2 are available.
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